Bluefish Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
- Paid Up Capital ₹ 2.40 Cr
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 17.80%
- Profit Growth 61.46%
- Ebitda 58.93%
- Net Worth -18.90%
- Total Assets -17.84%
About Bluefish Pharmaceuticals
Bluefish Pharmaceuticals Private Limited (BPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 28 September 2006 and has a history of 18 years and four months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 2.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Astha Sehgal, Erik Ekman, and Vivekanandan Sundaramurthy serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U02423KA2006PTC049950
-
Company No.
049950
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Sep 2006
-
Date of AGM
15 Jul 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Bluefish Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Astha Sehgal
|
Director | 19-Nov-2021 | Current |
Erik Ekman
|
Director | 07-Sep-2022 | Current |
|
Vivekanandan Sundaramurthy
|
Director | 23-Aug-2021 | Current |
Financial Performance of Bluefish Pharmaceuticals.
Bluefish Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 17.8% increase. The company also saw a substantial improvement in profitability, with a 61.46% increase in profit. The company's net worth observed a substantial decline by a decrease of 18.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bluefish Pharmaceuticals?
In 2021, Bluefish Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bluefish Pharmaceuticals?
Bluefish Pharmaceuticals has a workforce of 81 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bluefish Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bluefish Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
